Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation

Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e630-e634. doi: 10.1016/j.clml.2021.03.001. Epub 2021 Mar 19.

Authors

Daniel Sherbenou¹, Margaret Stalker¹, Peter Forsberg¹, Tomer Martin Mark²

Affiliations

¹ University of Colorado Denver-Anschutz Medical Campus, Aurora, CO.
² University of Colorado Denver-Anschutz Medical Campus, Aurora, CO. Electronic address: [email protected].

PMID: 33863694
DOI: 10.1016/j.clml.2021.03.001

No abstract available

Keywords: Carfilzomib; Daratumumab; Elotuzumab; Pomalidomide; Sine.

Publication types

Case Reports

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Dexamethasone / administration & dosage
Hematopoietic Stem Cell Transplantation*
Humans
Hydrazines / administration & dosage*
Male
Multiple Myeloma / pathology
Multiple Myeloma / therapy*
Neoplasm Recurrence, Local / diagnosis
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / pathology
Oligopeptides / administration & dosage
Transplantation, Homologous
Treatment Outcome
Triazoles / administration & dosage*

Substances

Hydrazines
Oligopeptides
Triazoles
selinexor
carfilzomib
Dexamethasone